N-nonyloxypentyl-L-deoxynojirimycin reduces Stenotrophomonas maltophilia virulence in vitro and in Galleria mellonella infection model
Frontiers in Microbiology · 29.05.2026 · 17
DOI: 10.3389/fmicb.2026.1835243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 29.05.2026. Verfasst von Maria Stabile und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Stenotrophomonas maltophilia is an opportunistic pathogen able to resist multiple classes of antibiotics and form robust biofilms, making it difficult to treat.
Methods
The antimicrobial and anti-virulence activity of the iminosugar N -nonyloxypentyl-L-deoxynojirimycin (L-NPDNJ) against S. maltophilia was evaluated by in vitro and in vivo models. Results and discussion L-NPDNJ exhibited weak bactericidal activity but showed additive effects when used in combination with amikacin and tobramycin, reducing their minimum inhibitory concentrations by two- to threefold. At sub-inhibitory concentrations, L-NPDNJ was found to significantly modulate the expression of genes involved in antibiotic resistance, biofilm regulation, and virulence, including those encoding efflux pumps, global regulators, and extracellular proteases. These transcriptional changes were found to be associated with significant phenotypic effects. At sub-inhibitory concentrations, L-NPDNJ reduced cell surface hydrophobicity by up to 90%, impaired adhesion to abiotic surfaces and to human lung epithelial cells by over 90%, and disrupted preformed biofilms, decreasing biofilm biomass and metabolic activity by approximately 70%. In addition, L-NPDNJ has been shown to enhance macrophage phagocytosis and reduce intracellular bacterial survival, while improving epithelial cell viability. Notably, pretreatment of S. maltophilia cells with L-NPDNJ led to a substantial reduction in bacterial virulence in the Galleria mellonella infection model in a dose-dependent manner.
Conclusion
Collectively, these findings demonstrate that L-NPDNJ exerts a broad anti-virulence effect against S. maltophilia and suggest its potential application as an adjuvant strategy to improve the treatment of infections caused by this multidrug-resistant pathogen.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
- Department of Public Health, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Department of Chemical Sciences, University of Naples Federico II, Naples, Italy.
- Department of Laboratory Medicine, U.O.C Patologia Clinica, Ospedale del Mare-ASL Napoli 1 Centro, Naples, Italy.
Zitieren
APA
Stabile, M., Esposito, A., Migliaccio, A., Sepe, L., Artiano, R., Ricca, A., Iula, V. D., Zarrilli, R., Guaragna, A., & De Gregorio, E. (2026). N-nonyloxypentyl-L-deoxynojirimycin reduces Stenotrophomonas maltophilia virulence in vitro and in Galleria mellonella infection model. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1835243
Vancouver
Stabile M, Esposito A, Migliaccio A, Sepe L, Artiano R, Ricca A, et al. N-nonyloxypentyl-L-deoxynojirimycin reduces Stenotrophomonas maltophilia virulence in vitro and in Galleria mellonella infection model. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1835243
BibTeX
@article{Stabile2026,
author = {Stabile, Maria and Esposito, Anna and Migliaccio, Antonella and Sepe, Leandra and Artiano, Rosaria and Ricca, Antonella and Iula, Vita Dora and Zarrilli, Raffaele and Guaragna, Annalisa and De Gregorio, Eliana},
title = {N-nonyloxypentyl-L-deoxynojirimycin reduces Stenotrophomonas maltophilia virulence in vitro and in Galleria mellonella infection model},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1835243}
}
EUVIMED